PL1669367T3 - Peptydy, które mogą wiązać się z transformującym czynnikiem wzrostu beta 1 (TGF-BETA1) - Google Patents

Peptydy, które mogą wiązać się z transformującym czynnikiem wzrostu beta 1 (TGF-BETA1)

Info

Publication number
PL1669367T3
PL1669367T3 PL04742049T PL04742049T PL1669367T3 PL 1669367 T3 PL1669367 T3 PL 1669367T3 PL 04742049 T PL04742049 T PL 04742049T PL 04742049 T PL04742049 T PL 04742049T PL 1669367 T3 PL1669367 T3 PL 1669367T3
Authority
PL
Poland
Prior art keywords
tgf
peptides
bind
growth factor
transforming growth
Prior art date
Application number
PL04742049T
Other languages
English (en)
Inventor
De Las Herrerias Javier Dotor
Vazquez Ana Belén Lopez
Sagastibelza Juan José Lasarte
Valtuena Jesus Prieto
Cuesta Francisco Borras
Original Assignee
Proyecto De Biomedicina Cima S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto De Biomedicina Cima S L filed Critical Proyecto De Biomedicina Cima S L
Publication of PL1669367T3 publication Critical patent/PL1669367T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL04742049T 2003-08-22 2004-07-05 Peptydy, które mogą wiązać się z transformującym czynnikiem wzrostu beta 1 (TGF-BETA1) PL1669367T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200302020A ES2304069B1 (es) 2003-08-22 2003-08-22 Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
EP04742049A EP1669367B1 (en) 2003-08-22 2004-07-05 Peptides which can bind to transforming growth factor beta 1 (tgf-beta1)
PCT/ES2004/000320 WO2005019244A1 (es) 2003-08-22 2004-07-05 Péptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-beta1)

Publications (1)

Publication Number Publication Date
PL1669367T3 true PL1669367T3 (pl) 2011-02-28

Family

ID=34203356

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04742049T PL1669367T3 (pl) 2003-08-22 2004-07-05 Peptydy, które mogą wiązać się z transformującym czynnikiem wzrostu beta 1 (TGF-BETA1)

Country Status (18)

Country Link
US (1) US7666841B2 (pl)
EP (1) EP1669367B1 (pl)
JP (1) JP4902352B2 (pl)
CN (1) CN100424093C (pl)
AT (1) ATE479702T1 (pl)
AU (2) AU2004266856A1 (pl)
BR (1) BRPI0413215A (pl)
CA (1) CA2535807A1 (pl)
CY (1) CY1110885T1 (pl)
DE (1) DE602004028949D1 (pl)
DK (1) DK1669367T3 (pl)
ES (2) ES2304069B1 (pl)
HR (1) HRP20100637T1 (pl)
PL (1) PL1669367T3 (pl)
PT (1) PT1669367E (pl)
RU (2) RU2333917C2 (pl)
SI (1) SI1669367T1 (pl)
WO (1) WO2005019244A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
JP5112322B2 (ja) * 2005-10-24 2013-01-09 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ 免疫応答調節剤の製造におけるＴＧＦ−β１インヒビターペプチドの使用
RU2420307C2 (ru) * 2005-10-24 2011-06-10 Проекто Де Биомедисина Сима, С.Л. ПРИМЕНЕНИЕ ИНГИБИРУЮЩИХ TGF-бета1 ПЕПТИДОВ ДЛЯ ПРИГОТОВЛЕНИЯ МОДУЛИРУЮЩЕГО ИММУННЫЙ ОТВЕТ АГЕНТА
ES2327088B1 (es) * 2007-08-20 2010-07-26 Proyecto De Biomedicina Cima S.L. Combinaciones terapeuticas para el tratamiento de las metastasis.
ES2337973B8 (es) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
ES2330826B1 (es) 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. Sistema para empaquetamiento de adenovirus de alta capacidad.
BRPI0915093A2 (pt) 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugados para a administração de compostos biologicamente ativos
BRPI1008815A2 (pt) * 2009-02-05 2018-02-14 Digna Biotech, S.L composições farmacêuticas compreendendo peptídeos inibidores de tgf-beta1
BR112012010755A2 (pt) 2009-11-05 2015-09-22 Proyecto Biomedicina Cima Sl constructo de gene que permite a expressão hepato-específica induzível de um polinucleotídeo de interesse em resposta a um agente indutor, vetor, genoma viral recombinante, vírion, método in vitro para a expressão de um polinucleotídeo de interesse em uma célula de origem hepática, composição farmacêutica e operador-promotor bi-direcional induzível adequado para a expressão hepato-específica induzível de dois polinucleotídeos de interesse por um agente indutor
RU2413769C1 (ru) * 2009-12-24 2011-03-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pET-32a, КОДИРУЮЩАЯ ГЕН ЛИГАНД-СВЯЗЫВАЮЩЕГО ДОМЕНА РЕЦЕПТОРА II ТИПА ТРАНСФОРМИРУЮЩЕГО ФАКТОРА РОСТА-β ЧЕЛОВЕКА (TβRII), ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ СЛИТНОГО БЕЛКА ТИОРЕДОКСИН/TβRII И СПОСОБ РЕНАТУРАЦИИ И ОЧИСТКИ ЦЕЛЕВОГО БЕЛКА TβRII
WO2012001196A2 (es) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos
KR101029705B1 (ko) * 2010-06-30 2011-04-18 (주)엔솔테크 신규 펩타이드 및 그 용도
EP2407534A1 (en) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Methods and reagents for obtaining transcriptionally active virus-like particles and recombinant virions
CN104053788A (zh) 2011-11-28 2014-09-17 加泰罗尼亚调查和高级研究机构 结肠直肠癌的预后方法和试剂盒
WO2013113755A1 (en) 2012-01-30 2013-08-08 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Reagents and methods for the treatment of diseases based on the inhibition of calcineurin - nfat signalling pathway
ES2791627T3 (es) 2012-11-12 2020-11-05 Inst Catalana Recerca Estudis Avancats Métodos y kits para el pronóstico del cáncer colorrectal
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
CA2928626C (en) 2013-11-14 2023-03-14 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
EP2878674A1 (en) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
WO2015101666A1 (en) 2014-01-03 2015-07-09 Fundación Biofísica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
US20170121685A1 (en) 2015-11-02 2017-05-04 Tigenix S.A.U. Mesenchymal stem cell-derived exosomes and their uses
JPWO2017110093A1 (ja) 2015-12-24 2018-10-11 学校法人同志社 ＴＧＦ−βシグナルに起因する障害を治療または予防するための医薬およびその応用
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
EP3659626A4 (en) 2017-07-26 2021-05-05 The Doshisha Drug for treating or preventing disorder caused by tgf- signalling, and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151396A (ja) * 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
WO2004041846A2 (en) * 2002-11-01 2004-05-21 Boys Town National Research Hospital INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES

Also Published As

Publication number Publication date
RU2008115678A (ru) 2009-10-27
AU2004266856A1 (en) 2005-03-03
AU2010212466A1 (en) 2010-09-09
SI1669367T1 (sl) 2010-11-30
CN100424093C (zh) 2008-10-08
BRPI0413215A (pt) 2007-06-19
CA2535807A1 (en) 2005-03-03
HRP20100637T1 (hr) 2010-12-31
EP1669367A1 (en) 2006-06-14
DE602004028949D1 (en) 2010-10-14
US7666841B2 (en) 2010-02-23
DK1669367T3 (da) 2010-11-08
AU2010212466B2 (en) 2012-07-19
JP2007525204A (ja) 2007-09-06
ATE479702T1 (de) 2010-09-15
PT1669367E (pt) 2010-12-07
JP4902352B2 (ja) 2012-03-21
CN1839149A (zh) 2006-09-27
WO2005019244A1 (es) 2005-03-03
US20070142275A1 (en) 2007-06-21
RU2333917C2 (ru) 2008-09-20
RU2455358C2 (ru) 2012-07-10
EP1669367B1 (en) 2010-09-01
RU2006109011A (ru) 2006-07-27
ES2351865T3 (es) 2011-02-11
ES2304069A1 (es) 2008-09-01
ES2304069B1 (es) 2009-08-12
CY1110885T1 (el) 2015-06-10

Similar Documents

Publication Publication Date Title
CY1110885T1 (el) Πεπτιδια που μπορουν να συνδεθουν στον αυξητικο παραγοντα μεταμορφωσης βητα 1 (tgf-beta1)
SI1615952T1 (sl) Metoda zdravljenja vnetnih bolezni z uporabo specifičnih veznih sredstev humanega angiopoetin
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
NO971902D0 (no) Bindingsmidler til CD23
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE557031T1 (de) Promotoren zur regulierung der genexpression in pflanzenwurzeln
EP1660682A4 (en) ANTISENSE MODULATION OF P38 MITOGEN-ACTIVATED PROTEIN KINASE EXPRESSION
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
DK1692517T3 (da) Anvendelse af ADAM 12 til diagnosticering af præeklampsi
IL157464A0 (en) Zinc finger binding domains for nucleotide sequence ann
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
WO2005040339A3 (en) Aptamers to human epidermal growth factor receptor-3
AU2003230144A8 (en) Peptides capable of inducing attraction to the axonal growth and their use for treating neurodegenerative diseases
DE50308032D1 (de) Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung
GB0201025D0 (en) The treatment of degenerative diseases
PL1704237T3 (pl) Ccamk biorąca udział w nodulacji i endomikoryzacji
WO2004004649A3 (en) Compositions and methods for the treatment of immune related diseases
DE602004028497D1 (de) Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
EP1494702A4 (en) COMPOSITION FOR STIMULATION OF NEW BONE INDUCTION